Results from pre-clinical research show iron-like compound hold promise for treating patients with glioblastoma, an aggressive brain cancer
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
Subscribe To Our Newsletter & Stay Updated
